Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ASF 1057

Drug Profile

ASF 1057

Alternative Names: ASF-1057; Monooctanoin/nicotinamide cream

Latest Information Update: 01 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astion Pharma A/S
  • Class Nonsteroidal anti-inflammatories; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Seborrhoeic dermatitis

Most Recent Events

  • 01 Feb 2018 ASF 1057 is still in phase III trials for Seborrhoeic dermatitis in France and Finland (Topical) (EudraCT2007-004649-14)
  • 01 Feb 2018 No recent reports on development identified - Phase-III for Seborrhoeic dermatitis in Denmark, Canada, Sweden and United Kingdom (Topical)
  • 06 Aug 2015 Phase-III development is ongoing in European Union and Canada (EudraCT2006-005637-37, EudraCT2007-004627-38, EudraCT2007-004649-14 )
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top